

Alexander Schuhmacher

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1381773/alexander-schuhmacher-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

32
papers

352
citations

7
h-index

18
g-index

38
ext. papers

470
ext. citations

8
avg, IF

3.95
L-index

#	Paper	IF	Citations
32	Changing R&D models in research-based pharmaceutical companies. <i>Journal of Translational Medicine</i> , 2016 , 14, 105	8.5	166
31	Models for open innovation in the pharmaceutical industry. <i>Drug Discovery Today</i> , 2013 , 18, 1133-7	8.8	76
30	The upside of being a digital pharma player. <i>Drug Discovery Today</i> , 2020 , 25, 1569-1574	8.8	23
29	Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?. <i>Journal of Translational Medicine</i> , 2018 , 16, 119	8.5	22
28	Leading Pharmaceutical Innovation 2018 ,		14
27	Pre-clinical evaluation of advanced nerve guide conduits using a novel 3D testing model. <i>International Journal of Bioprinting</i> , 2018 , 4, 123	6.2	12
26	Translational precision medicine: an industry perspective. <i>Journal of Translational Medicine</i> , 2021 , 19, 245	8.5	12
25	A Review of the Pharmaceutical R&D Efficiency: Costs, Timelines, and Probabilities 2016 , 60-79		5
24	R&D efficiency of leading pharmaceutical companies - A 20-year analysis. <i>Drug Discovery Today</i> , 2021 , 26, 1784-1789	8.8	4
23	Big Techs and startups in pharmaceutical R&D - A 2020 perspective on artificial intelligence. <i>Drug Discovery Today</i> , 2021 , 26, 2226-2231	8.8	2
22	The Pharmaceutical Industry is Opening Its R&D Boundaries 2016 , 334-361		1
21	New Innovation Models in Pharmaceutical R&D 2016 , 400-415		1
20	The Influence of Leadership Paradigms and Styles on Pharmaceutical Innovation 2016 , 416-447		1
19	Global Epidemiological Developments 2016 , 10-43		1
18	The Role of Modern Portfolio Management in Pharma Innovation 2016 , 448-459		1
17	Challenges and Options for Drug Discovery 2016 , 106-139		1
16	Systematic risk identification and assessment using a new risk map in pharmaceutical R&D. <i>Drug Discovery Today</i> , 2021 , 26, 2786-2793	8.8	1

- 15 Innovation: Key to Success in the Pharmaceutical Industry **2018**, 1-16 o
- 14 Introduction to the Book **2016**, 1-9
- 13 Translational Development **2016**, 224-243
- 12 Forty Years of Innovation in Biopharmaceuticals [Will the Next 40 Years Be as Revolutionary? **2016**, 244-275
- 11 Vaccines: Where Inertia, Innovation, and Revolution Create Value, Simultaneously and Quietly **2016**, 276-307
- 10 The Patient-Centric Pharma Company: Evolution, Reboot, or Revolution? **2016**, 308-333
- 9 Out-Licensing in Pharmaceutical Research and Development **2016**, 362-381
- 8 Trends and Innovations in Pharmaceutical R&D Outsourcing **2016**, 382-399
- 7 Patent Management Throughout the Innovation Life Cycle **2016**, 460-474
- 6 The Value of Pharmaceutical Innovation: Concepts and Assessment **2016**, 44-59
- 5 Financing Pharmaceutical Innovation **2016**, 80-105
- 4 Translational Medicine: Enabling the Proof of Concepts **2016**, 140-159
- 3 Preclinical Safety and Risk Assessment **2016**, 160-181
- 2 Developing Commercial Solutions for Therapeutic Proteins **2016**, 182-201
- 1 Can Innovation Still Be the Main Growth Driver of the Pharmaceutical Industry?. *Perspectives on Sustainable Growth*, **2015**, 39-68